IOVA
NASDAQIovance Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks62+350%
2026-03-012026-08-23
Mix3290d
- Insider15(47%)
- SEC Filings8(25%)
- Other7(22%)
- Earnings2(6%)
Latest news
25 items- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on August 20, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s
- INSIDERChief Commercial Officer Kirby Daniel Gordon converted options into 10,001 shares and covered exercise/tax liability with 2,436 shares, increasing direct ownership by 5% to 154,511 units (SEC Form 4) (withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Financial Officer Roche Corleen M. converted options into 49,995 shares and covered exercise/tax liability with 21,238 shares (SEC Form 4) to cover taxes4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.SCHEDULE 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRWhy Investors Are Watching These Healthcare MoversDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ:CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. ClearOne Advances Toward Neurotechnology Transformation ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of Vivani Medical (NASDAQ:VANI), which was first announced on July 2, as investors continue tracking milestones that could reshape the company's future. Clear
- SECSEC Form 10-Q filed by Iovance Biotherapeutics Inc.10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRIovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate UpdatesU.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates. "Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,
- PRIovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, August 6, 2026 at 8:30 a.m. ET to report its second quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/3f4w9ts7. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available
- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on July 16, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 139,930 shares of Iovance’s common stock to seventeen new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 18, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Compa
- INSIDERSEC Form 4 filed by Director Weiser Michael4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Dukes Iain D.4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Countouriotis Athena4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Maynard Ryan D4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Chief Regulatory Officer Puri Raj K.4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- SECSEC Form S-8 filed by Iovance Biotherapeutics Inc.S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECSEC Form S-8 filed by Iovance Biotherapeutics Inc.S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECSEC Form S-3ASR filed by Iovance Biotherapeutics Inc.S-3ASR - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- INSIDERInterim CEO & General Counsel Vogt Frederick G converted options into 15,625 shares and covered exercise/tax liability with 6,638 shares, increasing direct ownership by 2% to 562,492 units (SEC Form 4) (tax liability)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Medical Officer Graf Finckenstein Friedrich converted options into 7,813 shares and covered exercise/tax liability with 3,976 shares, increasing direct ownership by 3% to 140,111 units (SEC Form 4) (for withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Regulatory Officer Puri Raj K. converted options into 9,766 shares and covered exercise/tax liability with 3,843 shares, increasing direct ownership by 2% to 248,114 units (SEC Form 4) to cover withholding tax4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
IOVA FAQ
6 questionsWhat does Iovance Biotherapeutics Inc. do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance...Where does IOVA stock trade?
Iovance Biotherapeutics Inc. (IOVA) is listed on NASDAQ.What sector and industry is IOVA in?
Iovance Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about IOVA?
Iovance Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $500.00 price target on 2026-02-25.What companies are similar to IOVA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IOVA side-by-side with any of them on Quantisnow.How can I track IOVA on Quantisnow?
Quantisnow aggregates Iovance Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IOVA to receive live email and push alerts on every new disclosure.